Ariad leukemia pill Iclusig approved by EU

July 2, 2013

CAMBRIDGE, Mass. (AP) -- Ariad Pharmaceuticals Inc. said Tuesday that European Union regulators approved the marketing of its leukemia pill Iclusig.

Iclusig was approved for use against treatment-resistant chronic myeloid leukemia and for patients with acute lymphoblastic leukemia with a type of chromosome abnormality.

The Food and Drug Administration approved Iclusig in December as a treatment for both of those conditions.

Shares of Ariad lost 8 cents to $19.45 in afternoon trading.